Table 1 Parameters used in the analysis
From: The global impact and cost-effectiveness of a melioidosis vaccine
Values | References | |||
|---|---|---|---|---|
Risk of melioidosis (baseline) | See Additional file 1: Table S3(a) | |||
Relative risk of melioidosis by risk factor | ||||
- Age > 45 years | 2.01 (1.87, 2.15) | Estimated from literature | ||
- Diabetes | 6.50 (6.10, 6.93) | Estimated from literature | ||
- Chronic renal disease | 1.33 (1.20, 1.46) | Estimated from literature | ||
Probability of each condition given melioidosis infection (3 levels; high-, middle- and low-income geographies) | High | Middle | Low | |
Probability of acute disease with complications | 0.40 | 0.50 | 0.25 | Expert opinion |
Probability of acute disease without complications | 0.48 | 0.40 | 0.55 | Expert opinion |
Probability of chronic disease with systemic illness | 0.07 | 0.05 | 0.07 | Expert opinion |
Probability of chronic disease without systemic illness | 0.06 | 0.05 | 0.12 | Expert opinion |
Risk of death (relative risk for each condition) | ||||
Baseline risk of death (chronic disease without systemic illness) | Vary between geographies | Estimated | ||
Relative risk for acute disease with complications | 16.42 | Expert opinion | ||
Relative risk for acute disease without complications | 5.33 | Expert opinion | ||
Relative risk of chronic disease with systemic illness | 5.17 | Expert opinion | ||
Probability of intensive care unit admission among acute cases with complication | 0.62 (0.48, 0.75) | Expert opinion | ||
Economic parameters | ||||
Resource use | ||||
Length of hospital stay (LOS) | Median (95% CI) | Indian hospital data | ||
Intensive care unit (ICU) for acute disease with complication cases | 3.20 (0.58, 10.04) | |||
General hospitalisation | ||||
- Acute disease with complication | 13.85 (1.66, 34.71) | |||
- Acute disease without complication | 14.77 (2.51, 34.35) | |||
- Chronic disease with systemic illness | 18.19 (4.20, 41.61) | |||
- Chronic disease without systemic illness | 15.36 (1.06, 41.81) | |||
Treatment duration (days) | [10] | |||
- Parenteral regimens | 12 (10, 14) | |||
Meropenem or ceftazidime | ||||
- Oral regimens | 112 (84, 140) | |||
Trimethroprim/sulfamethoxazole or co-amoxiclav | ||||
Costs (USD, 2016) | ||||
Cost of vaccine (complete course) by country income level | Low 10.2 Middle 43.5 High 338.2 | [27] | ||
Cost per bed day | WHO-CHOICE | [31] | ||
Cost per ICU bed day | ||||
Ratio between ICU and general bed day by income level | High 2.56 Middle 7.92 Low 13.28 | See Additional file 1: Table S3(b) | ||
Antibiotics (per day), children aged < 15 years | High | Middle | Low | |
Meropenem | 46.78 | 59.47 | N/A | |
Ceftazidime | 27.89 | 3.44 | 3.44 | |
Trimethoprim/sulfamethoxazole | 0.91 | 0.05 | 0.05 | |
Co-amoxiclav | 0.71 | 1.41 | 1.41 | |
Antibiotics (per day), adults aged > 15 years | High | Middle | Low | |
Meropenem | 62.37 | 79.30 | N/A | |
Ceftazidime | 43.39 | 5.35 | 5.35 | |
Trimethoprim/sulfamethoxazole | 1.12 | 0.06 | 0.06 | |
Co-amoxiclav | 1.06 | 2.11 | 2.11 | |
Health-related quality of life (utility) | ||||
Bacteraemia | 0.36 (0.33, 0.38) | [28] | ||
General population | 0.84 | [29] | ||
Life expectancy | WHO Life Table | [23] | ||